Search Results
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
efficacy.In recent years, emerging approaches such as immunotherapy-based combinations and ADCs have brought new hope. However, multiple large-scale Phase III clinical trials in NSCLC patients who had failed both platinum-based chemotherapy and immunotherapy have not yet delivered satisfactory outcomes. Therefore,
More news about: Innovent Biologics
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
Q3W monotherapy demonstrated long-term survival benefits in the PoC study with updated data presented at this year's ASCO. A global multicenter Phase III MRCT trial (Marslight‑11) comparing IBI363 3mg/kg Q3W monotherapy head‑to‑head with docetaxel is currently ongoing.Moving into IO-naive
More news about: Innovent Biologics
May 31, 2026, 20:00 ET ImmVira Reports 100% Complete Response Rate at 9 Months in Bladder Carcinoma in Situ with MVR-T3011 at ASCO
of the final outcomes of the current study, nor should they be regarded as predictive of results that may be achieved in a future confirmatory phase III clinical trial or in connection with any regulatory review or approval.About MVR-T3011MVR-T3011,
More news about: ImmVira Group
May 31, 2026, 16:30 ET Berkshire Hathaway to Acquire Taylor Morrison Home Corporation for $8.5 Billion
satisfaction or waiver of other conditions to the completion of the proposed transaction, including obtaining required shareholder and regulatory approvals; (iii) the risk that Taylor Morrison's stock price may fluctuate during the pendency of the proposed transaction and may decline if the proposed transaction
More news about: Taylor Morrison Home Corporation
May 31, 2026, 09:00 ET HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session
improvement in overall survival (OS) as a first-line treatment for patients with advanced squamous non-small cell lung cancer (sq-NSCLC) in the Phase III HARMONi-6 (AK112-306) study. These landmark findings will be featured in a Plenary Session at the 2026 American Society of Clinical Oncology (ASCO) Annual
More news about: Akeso, Inc.
May 31, 2026, 08:29 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
LBA48 BURAN: A phase III study of buparlisib (BUP) plus paclitaxel (PAC) in patients with PD-1(PD-L1)-pretreated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Ann Oncol. 2025;36:S1707.7 Fayette J, et al. INTERLINK-1: A Phase III, randomized, placebo-controlled
More news about: Johnson & Johnson
May 31, 2026, 08:00 ET GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting
Breast, Colorectal, Cervical and Lung Cancer71% of the New Cancers Detected by the Galleri Test Were in Stages I-IIIMENLO PARK, Calif., May 31, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq:
More news about: GRAIL, Inc.
May 30, 2026, 20:00 ET Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the results of the Phase III clinical study OptiTROP-Lung05, evaluating the company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) sacituzumab
More news about: Kelun-Biotech
May 30, 2026, 20:00 ET 榮登《柳葉刀》主刊！蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗一線治療 PD-L1 陽性 NSCLC III期重磅結果發表
original content to download multimedia:https://www.prnewswire.com/apac/zh/news-releases/sac-tmt-pd-l1--nsclc-iii-302786278.htmlSOURCE 科倫博泰
More news about: 科倫博泰
May 30, 2026, 08:00 ET GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting
explained the reasons behind the Stage III and IV result: "We saw a substantial decrease in Stage IV cancers, but this was outweighed by an overall increase in the number of Stage III cancers, particularly in the prevalent screening round. We believe the Stage III increase was driven in part by a number
More news about: GRAIL, Inc.
May 29, 2026, 23:32 ET The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet
"Company", 6990.HK) announced today that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, the results of the Phase III clinical study OptiTROP-Lung05, evaluating the company's TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870)(佳泰莱®) in
More news about: Kelun-Biotech
May 29, 2026, 22:00 ET Sportradar Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Sportradar Group AG - SRAD
Sportradar's operations; (ii) the Company's Know-Your-Customer ("KYC") and compliance processes were not as robust as Defendants' had claimed; and (iii) as a result, the Company's statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable
More news about: ClaimsFiler
May 29, 2026, 22:00 ET SES AI Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against SES AI Corporation - SES
no operational capacity; (ii) the company created the appearance of revenue by purchasing services tied to its own Molecular Universe transactions; (iii) despite its optimistic growth statements, SES AI faced significant logistics constraints in Q4 2025 that materially impacted revenue for that quarter;
More news about: ClaimsFiler
May 29, 2026, 17:32 ET Harford Mutual Insurance Group Announces Board Reelections Following Annual Meeting
The board members reelected were Theodore M. Alexander III, Donald C. Fry, Sandra L. Rich, and Abigail E. Smith. Alexander and Rich were reelected to serve three-year terms. Fry, who currently serves as board
More news about: Harford Mutual Insurance Group
May 29, 2026, 17:30 ET Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice
subject to compliance with other listing requirements of the Company Guide.In connection with the non-compliance with Sections 1003(a)(ii) and (iii) of the Company Guide, the Company must submit a compliance plan by June 26, 2026, advising of actions the Company has taken or will take to regain compliance
More news about: Actinium Pharmaceuticals, Inc.
May 29, 2026, 12:22 ET J&J Exterminating Celebrates 65th Anniversary and Unveils Strategic Vision at Annual Team Meeting
while pursuing deliberate, sustainable expansion and deepening its community impact in the markets it serves over the coming years.Robert John III, COO of J&J Exterminating summed it up best during his speech stating, "So as we head into the rest of today — and into the year ahead — I want to
More news about: J&J Exterminating
May 29, 2026, 11:58 ET FIBRA Prologis Adquiere 590,000 Pies Cuadrados en el Mercado de la Ciudad de México
situación económica internacional, regional y local, (ii) los cambios en los mercados financieros, tasas de interés y tipos de cambio de moneda extranjera, (iii) aumento en, o surgimiento de, competencia respecto de nuestras propiedades, (iv) los riesgos asociados con adquisiciones, enajenación y desarrollo de
More news about: FIBRA Prologis
May 29, 2026, 11:57 ET FIBRA Prologis Adquiere 590,000 Pies Cuadrados en el Mercado de la Ciudad de México
situación económica internacional, regional y local, (ii) los cambios en los mercados financieros, tasas de interés y tipos de cambio de moneda extranjera, (iii) aumento en, o surgimiento de, competencia respecto de nuestras propiedades, (iv) los riesgos asociados con adquisiciones, enajenación y desarrollo de
More news about: FIBRA Prologis
May 29, 2026, 10:54 ET FIBRA Prologis Acquires 590,000 Square Feet in the Mexico City Market
national, international, regional and local economic climates, (ii) changes in financial markets, interest rates and foreign currency exchange rates, (iii) increased or unanticipated competition for our properties, (iv) risks associated with acquisitions, dispositions and development of properties, (v)
More news about: FIBRA Prologis
May 29, 2026, 10:00 ET Cyient Named Leader Across All Three Quadrants of ISG Provider Lens™ 2026 Digital Engineering Services Report for North America
www.cyient.com About ISGISG (Information Services Group) (Nasdaq: III) is a leading global technology research and advisory firm. A trusted business partner to more than 700 customers, including more than 75 of the top
More news about: Cyient
May 29, 2026, 10:00 ET Cyient Named Leader Across All Three Quadrants of ISG Provider Lens™ 2026 Digital Engineering Services Report for North America
www.cyient.com About ISGISG (Information Services Group) (Nasdaq: III) is a leading global technology research and advisory firm. A trusted business partner to more than 700 customers, including more than 75 of the top
More news about: Cyient
May 29, 2026, 09:08 ET Innogen to Present Phase IIb ENLIGHT Study Results for Efsubaglutide Alfa at the 2026 ADA Scientific Sessions
demonstrates the broad prospects of Efsubaglutide α in the field of obesity treatment and provides strong scientific evidence for the upcoming Phase III clinical trial. We will go all out to accelerate subsequent research, promoting the early implementation of this original Chinese achievement to benefit
More news about: Innogen Pharmaceuticals
May 29, 2026, 08:50 ET General Tool Company Announces Major Facility Expansion to Support Increased U.S. Navy Arleigh Burke Class Destroyer Production
The AG9160RF is the class-standard generator set for Flight III destroyers, providing the electrical power needed to support advanced systems, including the SPY-6 radar. Rolls-Royce GTGs have powered every U.S. Navy
More news about: General Tool Company
May 29, 2026, 07:00 ET COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
$217,000 decrease in the workforce expenses, (ii) a $257,000 decrease in research and development subcontractors expenses and materials expenses, and (iii) a $105,000 reduction in general and administrative public company expenses. On a non-GAAP basis, the operating expenses for the first quarter ending
More news about: CollPlant
May 29, 2026, 02:28 ET Aphranel® MagiCCrystal obtiene la certificación EU MDR
diciembre de 2027 ya no podrán seguir comercializándose en el mercado de la UE.El proceso de certificación duró 2 años y 7 meses bajo la vía de Clase III del MDR para dispositivos médicos implantables absorbibles de alto riesgo, sin vías de equivalencia ni exenciones.Para apoyar la consecución de
More news about: SHANGHAI MOYOM BIOTECHNOLOGY CO., LTD; Aphranel